L-arginine enhances blood trace metals and reduces oxidative stress burden in sickle cell anaemia subjects in the steady state by Ogungbemi, S.I. et al.
 
 
J. Afr. Ass. Physiol. Sci. 6 (2): 145-152, December 2018 
 
Journal of African Association of Physiological Sciences 







L-arginine enhances blood trace metals and reduces oxidative 
stress burden in sickle cell anaemia subjects in the steady state 
 
S. I. Ogungbemi, S.I. Jaja, C.N. Anigbogu and M.O. Kehinde* 





L-arginine, sickle cell 
anaemia, antioxidant 



















Background: It is not clear how arginine supplementation, which may be beneficial in the 
management of sickle cell anaemia, interplays with trace metals which are required as cofactors 
for antioxidant enzymes levels and activity. Methods: We compared the effect of oral, low-dose 
(1 g/day), 6-week supplementation with L-arginine on some trace metals and antioxidant 
enzymes levels in 33 HbAA and 28 HbSS subjects. Ten (10) milliliters of blood was withdrawn 
from an ante-cubital vein for the estimation of plasma arginine concentration ([R]), catalase 
(CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx) and malondialdehyde 
(MDA) levels and serum concentrations of Zn++, Mn++ and Cu++. Results: HbAA subjects had 
higher levels of Zn++, Mn++, [R], CAT, SOD and GPx but lower [MDA] (p < 0.05 in each case) 
than HbSS subjects. In both groups, L-arginine supplementation increased [R], SOD, GPx, CAT, 
Zn++ and Cu++ (p < 0.05 in each case and group) but decreased [MDA] (p < 0.001 in each group). 
Mn++ level decreased in HbAA but, it increased in HbSS subjects (p < 0.001 in each case). The 
degree of change (%∆) in all the measured parameters (except MDA) was higher in HbSS than 
in HbAA subjects. Correlation coefficients (r) calculated between changes (∆) in trace metals 
levels and changes (∆) in antioxidant levels were higher in HbSS subjects. Conclusion: Study 
showed that L-arginine boosted plasma arginine, serum trace metals and antioxidant enzymes 
but decreased malondialdehyde in HbSS subjects in the steady state. Associations between 
changes in antioxidant enzymes and changes in trace metal levels were higher in HbSS than in 
HbAA subjects. 
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INTRODUCTION   
Sickle cell haemoglobinopathy which arises from a 
replacement on the beta chain of haemoglobin of 
glutamic acid by valine at the 6th position (Ingram, 
1956) is common among black populations of the world. 
In Africa, the incidence of sickle cell anaemia (SCA) is 
between 5% and 40% (Diallo and Tchemia, 2012). The 
World Health Organisation (WHO, 1994) estimates that 
in Africa 120,000 to 200,000 babies are born each year 
with SCA while in Nigeria, the estimated annual number 
of HbSS neonates is about 85,000 (Piel et al., 2013). In 
the USA, sickle cell anaemia (SCA) is considered the 
most common haemoglobinopathy and it is estimated 
that about 100,000 individuals suffer from the disease 
(Hassel, 2010). 
 
Recent evidence suggests that supplementation with 
arginine may be beneficial in the management of sickle 
cell anaemia (SCA). Arginine is a naturally occurring 
basic amino acid which is involved in many important 
biochemical reactions associated with normal 
physiology. It is found in proteinous foods like meat, 
poultry, nuts and fish and also in watermelon. Arginine 
level has been shown to be low in adults with SCA in the 
steady state (Enwonwu et al., 1990; Morris et al., 2000) 
and in patients with SCA in vaso-occlusive crises and 
acute chest syndrome (Morris et al., 2000; Dasgupta et 
al., 2006). Children suffering from the disease, however, 
have plasma levels that are similar to normal controls 
(Morris et al., 2000). 
Although earlier studies had suggested the arginine-NO 
pathway as the major pathway for arginine activity in 
sickle cell anaemia (SCA) subjects (Morris et al., 2000; 
Styles et al., 2007; Bakshi and Morris, 2016), there may 
be other pathways through which arginine may exert its 
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beneficial effects. Arginine may have antioxidant effects 
since co-administration with hydroxyurea increased the 
plasma level of glutathione peroxidase in SCA patients 
(Little et al., 2009). In addition, arginine had been shown 
to increase total antioxidant enzymes (TAE) and 
decrease malondialdehyde (MDA) levels in SCA 
subjects (Kehinde et al., 2015). Furthermore, Jaja et al., 
(2016) showed that change in plasma arginine 
concentration (∆[R]) correlated negatively with change 
in some liver enzymes (aspartate aminotransferase, 
(AST), alanine aminotransferase, (ALT), and alkaline 
phosphatase, (ALP)) and change in [MDA] suggesting a 
role for arginine-antioxidant activity. In sickle cell 
mouse model, arginine increased erythrocyte glutathione 
levels (Romero et al., 2002) and protected against 
oxidative stress (Dasgupta et al., 2006). The levels of 
antioxidant enzymes in sickle cell anaemia had been 
found to be variable in the steady state. While some 
studies showed an increase, others showed a decrease in 
plasma levels of these antioxidants (Das and Nair, 1980; 
Dasgupta et al., 2006). It had been suggested that the 
increase in antioxidant enzymes may be protective; in 
order to scavenge hydrogen peroxide, while the 
decreased levels could be due to the overwhelming level 
of oxidative stress or reactive oxygen species (Chirico 
and Pialoux 2012).  
 
Antioxidant enzymes which include superoxide 
dismutase (SOD), catalase (CAT), glutathione 
peroxidase (GPx) and heme-oxygenase-1 (HO-1) are 
present as metallo-enzymes or metallo-proteins and 
require trace metals as cofactors. Superoxide dismutase 
requires copper, zinc and manganese as cofactors, while 
catalase requires iron as a cofactor to catalyse the 
decomposition of hydrogen peroxide (H2O2) to water 
and oxygen (Hyacinth et al., 2010). Glutathione 
peroxidase requires selenium as a cofactor and catalyses 
the degradation of H2O2 and hydro-peroxides at the 
expense of reduced glutathione (GSH) (Hyacinth et al., 
2010). Trace metals levels in blood had been reported as 
similar (Kehinde et al., 2010), lower (Olaniyi and 
Ariola, 2010) or higher (Akenami et al,. 1999) in HbSS 
subjects in the steady state when compared to their 
HbAA counterparts. Also, Kehinde et al, (2010) 
reported that plasma levels of Cu++, Zn++ or Mn++ in 
HbSS subjects in the acute phase or during pain crises 
were higher than those of HbAA subjects or HbSS 
subjects in the steady state.  
We have designed this study to investigate the effect of 
an oral, low dose (1 g/day), 6-week supplementation 
with L-arginine (Kehinde et al., 2015) on some trace 
metals and antioxidant enzymes levels in HbSS subjects 
with HbAA subjects serving as controls. The study also 
examined the relationship between the change in the 
serum levels of the trace metals and the antioxidant 
enzymes in both groups of subjects. 
 
MATERIALS AND METHODS 
Sixty one male and female adult subjects were recruited 
for the study after their medical history had been taken. 
Thirty three (33) participants were subjects without 
sickle cell anaemia (HbAA). They served as control 
subjects and were students of some tertiary institutions 
in Lagos, Nigeria. They were non-smokers and non-
alcoholics. Twenty eight (28) participants were sickle 
cell anaemia (HbSS) subjects. The red blood cell indices 
were done. The sickling test was performed using 
solubility (hard red band on top and colourless solution, 
using a freshly prepared buffer mixture and packed red 
cell from EDTA anticoagulation blood). The 
haemoglobin electrophoretic pattern was determined for 
confirmation (Dacie, 1991). Persons with the sickle cell 
trait (HbAS) were excluded from the study.  
The HbSS subjects were patients attending the Sickle 
Cell Out-Patients’ Clinic of The Lagos University 
Teaching Hospital, (LUTH), Idi-Araba, Lagos, Nigeria. 
They were in the steady state. None of the subjects had 
been admitted to the ward for pain crisis in the preceding 
six months. There was also no history of blood 
transfusion in the last twelve months. 
Institutional approval was obtained from the Ethics and 
Experimentation Committee of the College of Medicine 
of University of Lagos, Lagos, Nigeria. Each subject 
gave an informed consent before commencement of the 
study. 
In the laboratory, anthropometric data: age (years), 
height (meters) and weight (kilograms), were recorded. 
Ten millilitres (10 mL) of blood was withdrawn from an 
ante-cubital vein of each subject for the estimation of red 
blood cell indices, plasma arginine ([R]) and 
malondialdehyde ([MDA]) concentrations and also 
serum concentrations of catalase (CAT), superoxide 
dismutase (SOD) glutathione peroxidase (GPx), Zn++, 
Cu++ and Mn++ . L-Arginine (Mason Vitamins, Inc. 
Miami Lakes, Florida, USA.) was then administered to 
each subject orally at a dose of 1 g/day for 6 weeks. After 
6 weeks, the parameters were measured again. 
  Processing of all blood samples was done immediately 
after collection. Two millilitres (2 mL) of blood from 
each subject was put into a bottle containing ethylene-
diamine-tetraacetic acid (EDTA) for the measurement of 
red blood cell indices. Four millilitres (4 mL) was put 
into heparinised bottles and centrifuged at 3000 rpm for 
15 minutes to obtain plasma. The remaining 4 mL of 
blood was left standing in plain vacuum bottles to obtain 
serum. Plasma samples were collected using an ice 
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centrifuge machine. The plasma and serum samples 
were then stored within an hour at a temperature of – 20 
0C in a biofreezer.  
 
Determination of Plasma L-Arginine Concentration 
([R]) 
Plasma L-arginine concentration ([R]) (μmol/L) was 
determined using a modification of the Sakaguchi 
reaction (Kehinde et al., 2015). In order to determine the 
concentration of L-arginine in plasma, 1.0 mL of test 
plasma was used instead of 100% L-arginine. 
Absorbance was read on the Spectrophotometer and 
plasma L-arginine concentration (μmol/L) was 
calculated from the standard curve. L-Arginine 
concentration ([R], mg/L) was then converted to 
µmol/L. 
 
Determination of Serum Trace Metals Concentration 
Concentrations of Zn++, Mn++ and Cu++ in serum were 
determined using 2000 Series Bulk Scientific Atomic 
Absorption Spectrometer with a hollow cathode lamp 
and fuelled acetylene air mixture. The serum samples 
were aspirated and mean signal responses with each 
trace metal at its respective wavelength (Doherty et al., 
2010).  
 
Determination of Plasma Catalase Level 
Serum catalase (CAT) activity was assayed as described 
by Rukkumani et al, (2004). 0.01 M phosphate buffer, 
serum sample and 2 M hydrogen peroxide were 
combined to form a reacting mixture. The assay was then 
read at 620 nm on a spectrophotometer (at zero, 1, 2 and 
3 minutes).  CAT activity was calculated and expressed 
as U/mg protein. 
 
Determination of Plasma Superoxide Dismutase Level 
Serum superoxide dismutase (SOD) level was 
determined by measuring the inhibition of auto-
oxidation of epinephrine at pH 10.2 at a temperature of 
30 ⁰C as described by Rukkumani et al., (2004). 
Reagents used were 50 mM Na2CO3 buffer, plasma 
samples and epinephrine stock solution. Absorbance 
was read at 480 nm on a spectrophotometer. SOD 
activity was calculated and expressed as U/mg protein. 
 
Determination of Plasma Glutathione Peroxidase Level 
The serum glutathione peroxidase (GPx) level was 
measured as described by Ellman (1959), 0.4 M 
phosphate buffer (pH 7.0), 10 mM sodium azide, plasma 
samples, glutathione and H2O2 to form a reacting 
mixture. The supernatant was then treated with Ellman’s 
reagent. The absorbance was then read at 412 nm and 
GPx activity was calculated and expressed as U/mg 
protein (Rukkumani et al., 2004).  
 
Estimation of Plasma Malondialdehyde Concentration 
Plasma malondialdehyde concentration ([MDA]) was 
determined using plasma, thiobarbituric acid-
trichloroacetic acid- hydrochloric acid reagent to form a 
reacting mixture.  The mixture was heated in a boiling 
water bath for 15 minutes.  Flocculent precipitate was 
removed and absorbance was read at 535 nm. Plasma 
lipid peroxidation was then estimated as plasma [MDA] 
(Doherty et al., 2010). 
 
Data Analyses. 
Data was analysed and expressed as mean ± SEM. 
Statistical comparison was made using Student Neuman-
Keuls post-hoc ANOVA test. Significance was accepted 
when p < 0.05. Correlation coefficients (r) were also 
calculated between change (∆) in [R] and ∆ in serum 
concentrations of trace metals or antioxidant enzymes. 
      
RESULTS 
The anthropometric and haematologic characteristics of 
the subjects are shown in Table 1.  
 
Table 1: Physical and Haematological Parameters of 
HbAA and HbSS Subjects 
 
BMI = Body Mass Index; RBC = red blood cell; Hb = 
haemoglobin; PCV = packed cell volume; * = p <0.05; ** = 
p<0.01; *** = p <0.001 
 
The Table shows that the HbSS subjects were smaller in 
body weight and body mass index (BMI) than the HbAA 
subjects. Also the measured haematological parameters 
in the HbSS subjects were significantly less than in the 
HbAA subjects. Table 2 (a) Vs (b) shows that before 
supplementation with L-arginine, plasma [R], serum 
[Zn++], [Mn++], [CAT], [SOD] and [GPx] were 
significantly higher in HbAA than in the HbSS group (p 
< 0.001 in each case except Zn (p < 0.05)). However, 
[MDA] was significantly higher in HbSS group than in 
the HbAA group (p < 0.001).  Supplementation with L- 
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Table 3: Correlation Coefficients (r) between Measured 




* = p <0.05; ** = p <0.01; *** = p <0.001 
HbAA = control subject; HbSS = sickle cell anaemia subjects; 
Δ[R] = change in L-arginine concentration; Δ[Zn++] = change 
in Zinc concentration; Δ[Mn++] = change in Manganese 
concentration; Δ[Cu++] = change in copper concentration; 
Δ[CAT] = change in catalase concentration; Δ[GPx] = change 
in glutathione peroxide concentration; Δ[SOD] = change in  





arginine increased all the measured parameters in both 
groups except [MDA] that significantly decrease in the 
two groups (Table 2 (a) Vs (c) and (b) Vs (d)).  
 
 
Fig.1: Changes in plasma L-arginine and serum trace metals 
concentrations in HbAA and HbSS subjects following L-
arginine supplementation; HbAA = control subject ; HbSS = 
sickle cell; anaemia subject; Δ[R] = change in L-arginine 
concentration; Δ[Zn²⁺] = change in Zinc concentration, 
Δ[Mn²⁺] = change in Manganese concentration; Δ[Cu²⁺] = 
change in copper concentration; * = p < 0.05, *** = p < 0.001 
= significant . 
 
Figure 1 shows that supplementation caused 
significantly greater percent change (% ∆) in [R] (p < 
0.001), [Zn++] (p < 0.001), [Mn++] (p < 0.001) in HbSS 
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than in the HbAA group. Figure 2 shows that 
significantly greater increases (% ∆) occurred in [CAT] 
(p < 0.001), [SOD] (p < 0.001) and [GPx] (p < 0.001) in 
the HbSS subjects than in the HbAA subjects. Changes 
(% decrease) in [MDA] in the 2 groups were similar. 
 
 
Fig. 2: Changes in plasma antioxidant enzymes and 
malondialdehyde concentrations in HbAA and HbSS subjects 
following L-arginine supplementation; HbAA = control 
subject; HbSS = sickle cell anaemia subject, Δ[CAT] = change 
in catalase concentration; Δ[GPx] = change in glutathione 
peroxide concentration; Δ[SOD] = change in superoxide 
dismutase concentration; Δ[MDA] = change in 
malondialdehyde concentration; *** = p < 0.001 = significant 
 
 
Table 3 shows that in almost all cases the calculated 
correlation coefficients (r) between ∆ [R] and ∆ trace 
metals or antioxidant enzymes or between ∆ in 
antioxidants and trace metals were higher in the HbSS 
than in the HbAA group. 
 
DISCUSSION 
Our study shows that a six-week, oral, low dose arginine 
supplementation may impact oxidative stress by 
elevating antioxidant enzymes and trace metals levels 
but decreasing malondialdehyde (MDA) level. These 
findings are intriguing owing to failed oral arginine 
clinical trials in the past (Styles et al., 2007) which 
demonstrated no clinical effect with prophylactic doses 
considered to be sub-therapeutic in treating adults and 
children at steady-state. Kehinde et al., (2015) had 
highlighted different studies in which different high 
doses of L-arginine were used for varying durations of 
time. Those studies had employed higher doses over 
shorter periods of time. On the other hand, much lower 
dose (1 g/day) for a duration of six weeks had been 
shown to raise plasma arginine, reduced oxidative stress 
burden, and percent irreversibly sickle cell count and 
shifted the osmotic fragility curve to the right (Kehinde 
et al., 2015). Also, Jaja et al, (2016) had shown that 
using a similar protocol, arginine decreased MDA, total 
bilirubin and liver enzymes (ALT, AST and ALP) but 
elevated serum nitric oxide metabolite concentration 
([NOX]). The chronic (6 weeks) nature of this study may 
have contributed to recovery of arginine stores 
especially in the HbSS subjects. The magnitude of 
change (∆) in all the measured parameters was higher in 
HbSS subjects than in the HbAA control group, 
supporting earlier studies (Morris et al., 2000; Lopez et 
al., 2003) which showed that arginine metabolism was 
different between HbSS subjects and HbAA subjects. 
Plasma L-arginine was estimated using the modified 
Sakaguchi reaction method (Kehinde et al., 2015). No 
significant difference between measurements using the 
HPLC amino acid analyser and the modified Sakaguchi 
method had been reported (Li et al., 2008; Kehinde et 
al., 2015). Values for [R] obtained and reported in this 
study are comparable to those reported by earlier authors 
that estimated plasma arginine using other methods 
(Schnog et al., 2004; Luneburg et al., 2011).  Two (2) 
capsules of L-arginine (Mason Vitamins Inc. Miami 
Lakes, Florida, USA) contained L-arginine HCl (1000 
mg) and dicalcium phosphate (120 mg). The 
concentrations of the other constituents, gelatine 
(bovine), magnesium stearate, stearic acid and silica 
were not stated by the manufacturer and their 
contributions to the results are unknown. 
The lower plasma arginine concentration ([R]) seen in 
HbSS subjects agrees with earlier studies (Morris et al., 
2000; Scavella et al., 2010). However, arginine levels in 
children suffering from SCD had been found to be 
similar to those of normal children but low in children 
suffering from vaso-occlusive crises (VOC) (Morris et 
al., 2000). Low arginine bioavailability had been 
associated with early mortality in adults with sickle cell 
anaemia (SCA) (Morris et al., 2005). In this study, 
supplementation with L-arginine elevated serum 
arginine levels in both groups of subjects. This result 
agrees with earlier studies in humans (Morris et al., 
2000; Scavella et al., 2010) and mouse model of sickle 
cell disease (Romero et al., 2002). 
Our results agree with earlier studies which showed that 
serum concentrations of catalase (CAT), superoxide 
dismutase (SOD) and glutathione peroxidase (GPx) 
were lower in SCA subjects in the steady state than in 
normal subjects (Dasgupta et al., 2006) but contradicts 
the results of Das and Nair,(1980) which showed the 
opposite. Also, the higher resting MDA level seen in the 
SCA group in this study agrees with earlier studies (Nur 
et al., 2011). The higher MDA level when combined 
with the lower level of the antioxidant enzymes is an 
indication of high oxidative stress burden in the SCA 
group.  Factors that contribute to high oxidative stress 
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burden in SCA are recurrent ischemia-reperfusion injury 
(Kaul and Hebbel, 2000), elevated cell-free 
haemoglobin (Reiter et al., 2002) and higher auto-
oxidation of sickle haemoglobin (Akohoue et al., 2007). 
The consequences of high oxidative stress burden in 
SCA include increased haemolysis (Gladwin et al., 
2010), endothelial damage (Hebbel et al., 2004) and 
reduced NOX activity (Nur et al., 2011), resulting in 
vaso-occlusion and organ damage (Hebbel et al., 2009). 
Supplementation with L- arginine elevated blood 
antioxidant enzymes (CAT, SOD and GPx) levels but 
reduced MDA levels in both groups of subjects. This 
agrees with earlier results in humans (Little et al., 2009; 
Jaja et al., 2016) and transgenic sickle mice (Dasgupta 
et al., 2006). When taken together our results suggest 
that low dose chronic supplementation with arginine 
may result in reduced oxidative stress burden. The level 
of enhancement of the antioxidant enzymes was greater 
in the HbSS group than in the HbAA group. This result 
is further corroborated by the higher positive 
correlations seen between change in serum arginine 
(∆[R]) and ∆CAT, ∆SOD or ∆GPx in HbSS group than 
in the control group (Table 3). Other authors had 
demonstrated in transgenic knockout sickle mice that 
arginine therapy reduced haemolysis and oxidative 
stress, improved nitric oxide metabolites (NOX) 
bioavailability and micro-vascular function (Kaul et al., 
2008). Morris et al, (2000) showed that arginine 
increased NOX in normal subjects and dose-dependently 
in SCA patients with vaso-occlusive crisis but decreased 
it in SCA patients in the steady state. Furthermore, it had 
also been shown in SCA subjects that arginine 
supplementation increased serum NOX but decreased 
MDA, total bilirubin (TB) and liver enzymes (ALT, 
AST and ALP) levels (Jaja et al., 2016). 
Serum concentrations of Zn++, Mn++ and Cu++ were 
lower in HbSS subjects than in the HbAA group. This is 
similar to earlier studies (Olaniyi and Ariola, 2010; 
Idonije et al., 2011) but different from those that 
observed higher values in HbSS subjects (Rukkumani et 
al., 2004). However, Kehinde et al, (2010) had reported 
that some trace metals concentrations were higher in 
SCA subjects in the acute (vaso-occlusive) phase than in 
healthy subjects. In sickle cell anaemia sufferers, 
deficient trace metals levels had been linked to deficient 
immune function, retarded growth hypogonadism in 
males, and delayed wound healing (Prassad, 2002; Silva 
and Marcos, 2005). Arginine supplementation caused 
increases in serum trace metals levels (except Mn++ in 
the HbSS group) in both groups of subjects. Greater 
increases were seen in the HbSS than in the HbAA group 
(except for Cu++). It is not clear how arginine 
supplementation increased the serum levels of the trace 
metals. However, since the sources of the trace metals 
are dietary it is likely that arginine might have enhanced 
intestinal absorption of these trace metals from food. 
Significant and positive correlations seen in this study 
between change in plasma arginine (∆[R]) and change in 
the various trace metals levels and also between ∆[R] 
and change in the various antioxidant enzymes levels 
corroborate our results that increased arginine levels 
resulted in elevated levels of trace metals and 
antioxidant enzymes. In addition, the significant and 
positive correlation between change in each of the 
antioxidant enzymes levels and change in each of the 
trace metals levels suggest a positive association 
between them. The correlation coefficients (r) between 
change in measured antioxidant enzymes and change in 
trace metal levels (Table 3) were higher in HbSS than in 
their HbAA counterparts. Trace metals are integral parts 
and are required as co-factors by antioxidant enzymes to 
function properly (Harris et al., 1992; Prassad 2002; 
Farell, 2010). Superoxide dismutase requires copper, 
zinc and manganese as cofactors (Farewell, 2010; 
Chirico and Pialoux, 2012). Glutathione peroxidase also 
requires manganese as a cofactor (Olaniyi and Ariola, 
2010) and catalyses the degradation of hydrogen 
peroxide (H2O2) and hydro-peroxides at the expense of 
reduced glutathione (GSH) (Chirico and Pialoux, 2010) 
while catalase requires iron as a cofactor to catalyse the 
decomposition of hydrogen peroxide (H2O2) to water 
and oxygen (Hyacinth et al., 2010). The study therefore 
showed a relationship between serum trace metals 
concentrations and plasma antioxidant enzymes levels in 
the HbSS subjects. This could be another mechanism by 
which arginine exerts its antioxidant effects. Arginine is 
less expensive and had been shown to be a safe and 
efficacious intervention with narcotic-sparing effects in 
the management of vaso-occlusive pain episodes 
(Morris et al., 2013; Bakshi and Morris, 2016).\ 
 
In conclusion, this study demonstrated that chronic, low-
dose, oral, arginine supplementation enhanced the 
recovery of arginine stores, elevated trace metals and 
antioxidant enzymes levels in the body. Elevation of 
trace metals levels may have contributed to the integrity 
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